You are here

  • Home
  • Archive
  • Volume 80, Issue 10
  • Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

Citation Tools

Article menu

Download PDFPDF

Letter
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Spiera R, Jinich S, Jannat-Khah D
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Annals of the Rheumatic Diseases 2021;80:1357-1359.